Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively  Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares to three new employees on March 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. Based on confidence in the long-term outlook for ZYNLONTA®, ADC Therapeutics negotiated mutually beneficial updated terms with HealthCare Royalty, offering greater strategic flexibility to the Company.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's common shares to seven new employees on February 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.